Pin Therapeutics

Pin Therapeutics, founded in 2017, is a biotechnology company focused on the field of targeted protein degradation. It is developing new platforms and screening systems, respectively named "PinE3" (for novel E3 ligases) and "PinGLUE" (for novel molecular glue degraders), aiming to address the limitations of current TPD technologies and develop a pipeline of drug candidates with clinical application prospects.